Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Edward C Stites"'
Autor:
Keesha E Erickson, Oleksii S Rukhlenko, Md Shahinuzzaman, Kalina P Slavkova, Yen Ting Lin, Ryan Suderman, Edward C Stites, Marian Anghel, Richard G Posner, Dipak Barua, Boris N Kholodenko, William S Hlavacek
Publikováno v:
PLoS Computational Biology, Vol 15, Iss 1, p e1006706 (2019)
Receptor tyrosine kinases (RTKs) typically contain multiple autophosphorylation sites in their cytoplasmic domains. Once activated, these autophosphorylation sites can recruit downstream signaling proteins containing Src homology 2 (SH2) and phosphot
Externí odkaz:
https://doaj.org/article/1ac9fae3f9c4494488487ff0d56be8a6
Autor:
Michael Trogdon, Kodye Abbott, Nadia Arang, Kathryn Lande, Navneet Kaur, Melinda Tong, Mathieu Bakhoum, J. Silvio Gutkind, Edward C. Stites
Publikováno v:
npj Systems Biology and Applications, Vol 10, Iss 1, Pp 1-17 (2024)
Abstract Mathematical models of biochemical reaction networks are an important and emerging tool for the study of cell signaling networks involved in disease processes. One promising potential application of such mathematical models is the study of h
Externí odkaz:
https://doaj.org/article/0b29339706f74b9f85438ba20cdd4062
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing.
Autor:
Winnie S Liang, David W Craig, John Carpten, Mitesh J Borad, Michael J Demeure, Glen J Weiss, Tyler Izatt, Shripad Sinari, Alexis Christoforides, Jessica Aldrich, Ahmet Kurdoglu, Michael Barrett, Lori Phillips, Hollie Benson, Waibhav Tembe, Esteban Braggio, Jeffrey A Kiefer, Christophe Legendre, Richard Posner, Galen H Hostetter, Angela Baker, Jan B Egan, Haiyong Han, Douglas Lake, Edward C Stites, Ramesh K Ramanathan, Rafael Fonseca, A Keith Stewart, Daniel Von Hoff
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e43192 (2012)
Pancreatic adenocarcinoma (PAC) is among the most lethal malignancies. While research has implicated multiple genes in disease pathogenesis, identification of therapeutic leads has been difficult and the majority of currently available therapies prov
Externí odkaz:
https://doaj.org/article/8bbd106cd51d413ca0f1e24b592ba757
Autor:
Yuriy Baglaenko, Catriona Wagner, Vijay G. Bhoj, Petter Brodin, M. Eric Gershwin, Daniel Graham, Pietro Invernizzi, Kenneth K. Kidd, Ilya Korsunsky, Michael Levy, Andrew L. Mammen, Victor Nizet, Francisco Ramirez-Valle, Edward C. Stites, Marc S. Williams, Michael Wilson, Noel R. Rose, Virginia Ladd, Marina Sirota
Publikováno v:
Cambridge Prisms: Precision Medicine, Vol 1 (2023)
Precision Medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle. Autoimmune diseases are those in which the body’s natural defense system loses disc
Externí odkaz:
https://doaj.org/article/bcf797b4c46e41e2bed7e76f1a48f825
Publikováno v:
Molecular & Cellular Oncology, Vol 9, Iss 1 (2022)
Genome sequenced samples from cancer patients helped identify roles of different mutation types and enabled targeted therapy development. However, critical questions like what are the gene mutation rates among the patients? or what genes are most com
Externí odkaz:
https://doaj.org/article/b851a127b3d54de68181f6bb07978732
Autor:
Edward C. Stites
Publikováno v:
Methods in Molecular Biology ISBN: 9781071630075
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a4eb6c4927c0df9e3a2f99529a2712c
https://doi.org/10.1007/978-1-0716-3008-2_15
https://doi.org/10.1007/978-1-0716-3008-2_15
Autor:
Elpiniki Nikolopoulou, Lauren R. Johnson, Duane Harris, John D. Nagy, Edward C. Stites, Yang Kuang
Publikováno v:
Letters in Biomathematics, Vol 5, Iss 0, Pp S137-S159 (2018)
The use of immune checkpoint inhibitors is becoming more commonplace in clinical trials across the nation. Two important factors in the tumour-immune response are the checkpoint protein programmed death-1 (PD-1) and its ligand PD-L1. We propose a mat
Externí odkaz:
https://doaj.org/article/4cb3caa303564b2486bd7010cfd6f73c
Autor:
Thomas McFall, Michael Trogdon, Anita C. Guizar, John F. Langenheim, Laura Sisk-Hackworth, Edward C. Stites
Publikováno v:
npj Precision Oncology. 6
The combination of KRAS G12C inhibitors with EGFR inhibitors has reproducibly been shown to be beneficial. Here, we identify another benefit of this combination: it effectively inhibits both wild-type and mutant RAS. We believe that targeting both mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8359fdfb4d28db4349002ecf3417d876
https://doi.org/10.1038/s41698-022-00329-w
https://doi.org/10.1038/s41698-022-00329-w
The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::039db278b371f661d65aafb454de84e5
https://doi.org/10.1017/9781009064828
https://doi.org/10.1017/9781009064828
Autor:
Edward C. Stites, Steven C. Plaxe, Thomas McFall, Ramez N. Eskander, Kasey Bamel, Sadakatsu Ikeda, Barbara A. Parker, Shumei Kato, Razelle Kurzrock, Kenta Takahashi
Publikováno v:
The Oncologist
We report on a woman with aggressive estrogen receptor‐positive, KRAS‐mutated ovarian cancer who achieved a remarkable response to combination therapy with the MEK inhibitor (trametinib) and the aromatase inhibitor (letrozole), even though the di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce0e453f4936a0518df580ed06699ff2
http://europepmc.org/articles/PMC8018312
http://europepmc.org/articles/PMC8018312